Genetic differences may help explain responses to female infertility treatments
A descriptive review catalogued variants linked to medication response, while identifying gaps in reproductive conditions and evidence needed for clinical use.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review identified genetic variants associated with responses to female infertility medicines. These links may help researchers investigate why treatment responses differ, including reduced effectiveness or excessive responses. The abstract does not show that using genetic tests to select treatment improves pregnancy outcomes, prevents adverse effects, or provides a proven clinical decision tool.
This abstract-based account contains no named variant-drug comparisons, effect estimates, or outcomes from testing-guided care. It cannot establish which associations are ready to guide an individual treatment choice.
A map of reported associations
Researchers searched a medical literature database and summarized 46 genetic variants linked to drug response. This is a map of reported associations; the abstract does not describe the strength or consistency of each individual link.
Gaps across reproductive medicine
The authors highlight research gaps for endometriosis and uterine fibroids, conditions that can affect reproductive outcomes. Findings from infertility therapies therefore do not establish how genetic testing would perform across female reproductive medicine.
The original publication
Descriptive overview of gene variants potentially affecting female infertility treatments: A systematic review.
Martinez-Martinez A, Sanz FJ, Garcia-Acero P et al.
Biomed Pharmacother · 2026
- PubMed ID
- 41496343
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.